---
schema_version: "secwatch.filing_event.v1"
accession: "0001367644-25-000010"
form_type: "8-K"
ticker: "EBS"
cik: "0001367644"
company_name: "Emergent BioSolutions Inc."
filed_at: "2025-01-14T23:59:59+00:00"
generated_at: "2026-05-28T01:51:30.964621+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Emergent gains exclusive U.S./Canada commercial rights to Hikma's KLOXXADO 8 mg naloxone spray

## Summary
- Six-year agreement gives Emergent exclusive rights to market and distribute KLOXXADO (naloxone HCl) 8 mg nasal spray in U.S. and Canada.
- KLOXXADO complements existing OTC NARCAN 4 mg spray, offering higher-dose prescription option for opioid overdose reversal.
- Hikma will continue manufacturing KLOXXADO; product will be integrated into Emergent's NARCANDirect distribution network.
- CEO Joe Papa cites expanded product options to help reduce opioid overdose deaths and meet diverse patient and community needs.

## SEC filing metadata
- accession: 0001367644-25-000010
- form_type: 8-K
- ticker: EBS
- cik: 0001367644
- company_name: Emergent BioSolutions Inc.
- filed_at: 2025-01-14T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1367644/000136764425000010/0001367644-25-000010-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1367644/000136764425000010/ebs-20250114.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001367644-25-000010
- JSON: https://secwatch.observer/filing/0001367644-25-000010.json
- Plain text: https://secwatch.observer/filing/0001367644-25-000010.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.